Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

Biotechnology

Healthcare
$2.03 +2.84%

+$0.11 today

Market cap
$171.45M
Beta
0.97
P/E (TTM)
-5.5
EPS (TTM)
-$0.70
52W Low $1.35High $4.60

Volume 1.12M

Average 1.37M

ELDN Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Eledon Pharmaceuticals, Inc.NASDAQ: ELDN

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 112.42M shares rose 45.8% year over year, behind the +48.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 49.0% from the prior quarter. Over 3 fiscal years it compounded at +78.9% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +45.8% toward the trailing-twelve-month pace of +48.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
112.42M+49.0% QoQ
Last fiscal yearDec 2025
81.84M+68.6% YoY
LTMMar 2026
85.54M+48.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+45.8%——
1 year+68.6%——
3-year CAGR+78.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
81.84M USD
Year-over-year change
+68.6%
4-year CAGR
+53.3%

Weighted Avg Shares vs competitors

How ELDN compares with its peers on the latest reported figures

  • ELDN's LTM Mar 2026 weighted avg shares of 85.54M shares is the 4th highest of the 11 companies compared; the peer median is 59.01M shares.
  • Its year-over-year change of +48.0% is the highest of 11, against a peer median of +7.6%.
  • Over three fiscal years its annual growth of +78.9% compares with a peer median of +12.5%.
ELDN Competitors Peer median
Weighted Avg Shares for ELDN and competitors
Company Period LTM YoY 3-year CAGR
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
HUMAHumacyte, Inc.LTM Mar 2026167.44M +37.1%+15.3%
EDITEditas Medicine, Inc.LTM Mar 202690.28M +9.3%+8.9%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 202685.54M +48.0%+78.9%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
VNDAVanda Pharmaceuticals Inc.LTM Mar 202659.11M +1.3%+1.4%
VYGRVoyager Therapeutics, Inc.LTM Mar 202658.91M +1.6%+15.2%
ABEOAbeona Therapeutics Inc.LTM Mar 202654.09M +20.9%+88.9%
PBYIPuma Biotechnology, Inc.LTM Mar 202650.31M +2.7%+3.8%
ACHVAchieve Life Sciences, Inc.LTM Mar 202648.09M +39.5%+60.3%
TRDAEntrada Therapeutics, Inc.LTM Mar 202641.5M +5.9%+9.8%
Peer median (excluding ELDN) 59.01M+7.6%+12.5%

Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development23.74M27.08M30.31M51.96M66.27M
Selling, General & Admin13.13M12.7M12.69M18.61M16.98M
Operating Expenses36.87M88.43M43M70.58M83.25M
Depreciation & Amortization195K373K374K359K313K
EBITDA(36.67M)(39.41M)(116.16M)(35.39M)(45.27M)
EBITDA Margin—————
Operating Income(36.87M)(88.43M)(43M)(70.58M)(83.25M)
Operating Margin—————
Interest Income00000
Interest Expense00000
Other Income / Expenses7K462K(73.54M)34.82M37.67M
Income Before Tax(36.86M)(87.97M)(116.54M)(35.75M)(45.58M)
Pre-Tax Margin—————
Income Tax Expense(2.35M)00431K35K
Net Income(34.51M)(87.97M)(116.54M)(36.18M)(45.62M)
Net Margin—————
EPS (Basic)(2.33)(6.16)(4.73)(0.75)(0.56)
EPS (Diluted)(2.33)(6.16)(4.73)(0.75)(0.56)
Weighted Avg Shares14.82M14.29M24.62M48.54M81.84M
Weighted Avg Shares (Diluted)14.82M14.29M24.62M48.54M81.84M

Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

Intrinsic Alpha fair value

Locked

Current Price

$2.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.